GSK orders Sirtris execs to stop selling resveratrol

GlaxoSmithKline (NYSE: GSK) has ordered two Sirtris executives--Christoph Westphal and Michelle Dipp--to stop selling a resveratrol dietary supplement based on the drug the two companies have in development. In 2008, GSK forked over $720 million for access to Sirtris' pipeline of drugs based on resveratrol, a compound found in red wine that's thought to increase longevity. Many consumers have been clamoring for access to resveratrol after news report touting its anti-aging...